As we enter the fall, we reflect on our industry and highlight some of our recent work.
Perspective serves clients that operate across the continuum of healthcare—including biopharmaceuticals, diagnostics, healthcare technology / digital health, and precision medicine. Paradigm shifting treatments addressing a wide range of disease are on the horizon, bringing the need to address unique complexities in policy, market access, manufacturing, and distribution. In light of this, our clients are asking us to identify leaders with both traditional executive experience and evidence of flexibility and learning agility—leaders who can help maximize this period of unprecedented scientific and technological advance for the sake of patients and investors alike.
With respect to our Board and Executive Search work, please find highlights listed below.
- Alkermes, Director — Richard Gaynor, M.D. (President of Research and Development, Neon Therapeutics)
- Alkermes, Director — Andy Wilson (Former Chief Financial Officer, PerkinElmer)
- CRISPR Therapeutics, Director — Katherine High, M.D. (President and Head of R&D, Spark Therapeutics)
- CRISPR Therapeutics, Director — John T. Greene (Former Executive Vice President and Chief Financial Officer, Bioverativ)
- Erytech Pharmaceuticals, Director (Chairperson) — Jean-Paul Kress, M.D. (Former President and CEO and a member of the Board of Directors, Syntimmune)
- Insulet Corporation, Director — Corinne Nevinny (General Partner, LMNVC)
- Insulet Corporation, Director — Jim Hollingshead, Ph.D. (President, Sleep Business, ResMed)
- Rhythm Pharmaceuticals, Director — Stuart Arbuckle (Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals)
- Ziopharm Oncology, Director — Heidi Hagen (Co-Founder and Chief Strategy Officer, Vineti)
Chief Executive Officer | Chief Operating Officer
- Adaptimmune Therapeutics, Chief Executive Officer — Adrian Rawcliffe
- Atara Biotherapeutics, President, Chief Executive Officer, Member of Board — Pascal Touchon, D.V.M.
- Collegium Pharmaceutical, Executive Vice President, Strategy and Corporate Development — Bart Dunn
- Carisma Therapeutics, Chief Business Officer — Tom Wilton
- Blueprint Medicines, SVP, Market Access — Lauren (Geyer) Barnes, M.H.S.
- Sarepta Therapeutics, GM and Head of US Commercial — Maria Törnsén, M.Sc.
- Trinity Partners, SVP, Commercial — Kirsten Calvert Brady
- bluebird bio, Chief Financial Officer — William (Chip) Baird
Research & Development
- AGTC, Chief Medical Officer — Theresa G.H. Heah, M.D.
- ImmunoGen, VP, Clinical Operations — Ken Dhimitri, M.S.
- Seattle Genetics, Program Team Leader, Portfolio Strategy & Management — Samir Vattompadam, M.S.
- Tempus Labs, SVP, Data Science — Martin Stumpe, Ph.D.